These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Fraser GL; Lederman S; Waldbaum A; Kroll R; Santoro N; Lee M; Skillern L; Ramael S Menopause; 2020 Apr; 27(4):382-392. PubMed ID: 32102086 [TBL] [Abstract][Full Text] [Related]
7. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Santoro N; Waldbaum A; Lederman S; Kroll R; Fraser GL; Lademacher C; Skillern L; Young J; Ramael S Menopause; 2020 Dec; 27(12):1350-1356. PubMed ID: 32769757 [TBL] [Abstract][Full Text] [Related]
8. Fezolinetant: First Approval. Lee A Drugs; 2023 Aug; 83(12):1137-1141. PubMed ID: 37462862 [TBL] [Abstract][Full Text] [Related]
9. Deal watch: Neurokinin 3 receptor antagonist revival heats up with Astellas acquisition. Cully M Nat Rev Drug Discov; 2017 May; 16(6):377. PubMed ID: 28559557 [No Abstract] [Full Text] [Related]
10. Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Depypere H; Lademacher C; Siddiqui E; Fraser GL Expert Opin Investig Drugs; 2021 Jul; 30(7):681-694. PubMed ID: 33724119 [No Abstract] [Full Text] [Related]
11. Scaffold hopping of fused piperidine-type NK3 receptor antagonists to reduce environmental impact. Yamamoto K; Inuki S; Ohno H; Oishi S Bioorg Med Chem; 2019 May; 27(10):2019-2026. PubMed ID: 30975505 [TBL] [Abstract][Full Text] [Related]
12. Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal. Gompel A; Stuenkel CA Cell Rep Med; 2023 Jun; 4(6):101076. PubMed ID: 37343519 [TBL] [Abstract][Full Text] [Related]
13. Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2). Santoro N; Nappi RE; Neal-Perry G; English M; King DD; Yamaguchi Y; Ottery FD Menopause; 2024 Apr; 31(4):247-257. PubMed ID: 38517210 [TBL] [Abstract][Full Text] [Related]
14. More promising news (mostly) on manipulating neurokinin B activity as a nonhormonal treatment of hot flashes. Reame NK Menopause; 2020 Apr; 27(4):375-376. PubMed ID: 32132443 [No Abstract] [Full Text] [Related]